Navigation Links
Esperance Pharmaceuticals Announces Completion of Run-in Enrollment of Phase 2 Study of EP-100 Plus Paclitaxel in Advanced Ovarian Cancer

BATON ROUGE, La., Aug. 28, 2012 /PRNewswire/ -- Esperance Pharmaceuticals today announced the completion of the run-in cohort of its Phase 2, randomized, multi‐center trial of EP‑100 in combination with paclitaxel for patients with advanced ovarian cancer. EP‐100 is a targeted membrane‐disrupting peptide (tMDP) designed to seek and destroy cancer cells that over‐express luteinizing hormone releasing hormone (LHRH) receptors on their surfaces. LHRH receptors are over‐expressed in a wide range of cancers including ovarian cancer. In June, the Company presented results from the successful completion of a Phase 1 study of EP‑100 in advanced solid tumors at the American Society of Clinical Oncology (ASCO) Annual Meeting.

"We are pleased with the continued momentum behind EP‑100 and the progress of enrollment as we begin the randomized treatment phase," said Dr. Hector Alila, CEO of Esperance. "We are encouraged with early results, and look forward to accelerating enrollment in a very important, underserved patient population and providing an update on the clinical progress over time."

The randomized, Phase 2 trial of EP‑100 in combination with paclitaxel versus paclitaxel alone in patients with histologically confirmed epithelial ovarian carcinomas expressing LHRH‐receptors is actively enrolling patients in key clinical sites across the United States. Rationale for the study is based on the positive clinical evidence from escalating doses in 38 patients in the Phase 1 study and on preclinical studies showing synergies between EP‑100 and various chemotherapeutic agents.

About EP‑100

EP‑100, the lead candidate from Esperance's Cationic Lytic Peptide (CLYP™) platform technology, is a targeted membrane‐disrupting peptide (tMDP) designed to seek and destroy cancer cells that overexpress luteinizing hormone releasing hormone (LHRH) receptors on their surfaces. LHRH receptors are over‐expressed in a wide range of cancers including breast, prostate, endometrial, pancreatic, ovarian, blood, skin and testicular cancers. Results from pre‐clinical studies of EP‑100 have shown that the drug regresses established tumors in breast, prostate, ovarian and endometrial cancer xenografts in mice.

About Esperance Pharmaceuticals

Esperance Pharmaceuticals, Inc. is a clinical stage company developing a new class of targeted anticancer drugs using its Cationic Lytic Peptide (CLYP™) platform technology. These drug candidates, called targeted membrane‐disrupting peptides (tMDPs) and antibody drug conjugates (ADCs) selectively seek and destroy cancer cells, including cells known to be resistant to chemotherapeutic drugs, without harming normal cells. Targeting occurs through binding to specific receptors and antigens on the cell's surface. The Company was founded on patented technology discovered by scientists at the Pennington Biomedical Research Center, the Louisiana State (LSU) Ag Center and LSU main campus. Founding investors include the Louisiana Fund I, Themelios Ventures and Research Corporation Technologies. Additional investors include Sanofi, Advantage Capital Partners, Louisiana Technology Fund and private investors. More information can be found at

SOURCE Esperance Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals to Present at the Rodman & Renshaw 14th Annual Healthcare Conference
2. Alder Biopharmaceuticals Receives $3.5 Million Milestone Payment from Bristol-Myers Squibb for Initiation of Phase 2 Clinical Trial of ALD518/BMS-945429 in Crohns Disease
3. Vanda Pharmaceuticals to Participate in Two September Healthcare Investor Conferences
4. AcelRx Pharmaceuticals to Present at Three Upcoming Investor Conferences
5. Actinium Pharmaceuticals Strengthens Management Team
6. Alexza Pharmaceuticals to Present at the Stifel Nicolaus 2012 Healthcare Conference
7. Imprimis Pharmaceuticals Signs Agreement With DPT Labs For Clinical Supplies In Advance Of Planned Phase 3 Studies For Its Ketoprofen-Based Topical Anti-Inflammatory Drug
8. Access Pharmaceuticals To Host Second Quarter Investor Call on Thursday, August 23, 2012
9. Lexicon Pharmaceuticals Reports Preliminary Results From Two Phase 1 Studies
10. Nouveau Life Pharmaceuticals (NOUV) Releases Calcium & Vitamin D for Strong Bones
11. Isis Pharmaceuticals Announces Redemption Of 2 5/8% Convertible Subordinated Notes Due 2027
Post Your Comments:
(Date:12/1/2015)... , Dec. 1, 2015 During ... in San Francisco, CA , ... to the coronary marketplace. During a satellite symposium, ... Stent Design to Minimize Restenosis", a renowned physician ... available Medinol NIRxcell™ CoCr Coronary Stent System and ...
(Date:12/1/2015)... DUBLIN , Dec. 01, 2015 ... addition of the "Veterinary Equipment and Disposables ... to 2020" report to their offering. ... of the "Veterinary Equipment and Disposables Market ... 2020" report to their offering. --> ...
(Date:12/1/2015)... , Dec. 1, 2015   MabVax Therapeutics Holdings, ... company, announces it has filed an Investigational New Drug ... (FDA) for the Company,s lead fully human antibody product ... acceptance, MabVax plans to initiate the Phase I clinical ... --> The planned Phase I trial ...
Breaking Medicine Technology:
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... their independence is everything. That is why Hollister Incorporated has launched the VaPro ... offer this next product in the VaPro touch free catheter portfolio,” said Michael ...
(Date:12/1/2015)... ... December 01, 2015 , ... Next IT Healthcare, the leader ... in this year’s Fierce Innovation Awards: Healthcare Edition, an awards program from the ... finalist in the category of Digital Solutions for its innovative, industry-leading product, Alme ...
(Date:12/1/2015)... ... December 01, 2015 , ... TCS Healthcare Technologies (TCS), ... population health arenas, is pleased to announce that VIP Care Services, a Caprock ... implemented the ACUITY Complete Care™ Management to back their collaborative catastrophic case management ...
(Date:12/1/2015)... ... December 01, 2015 , ... PartnerTech , a leader ... leadership since 2008. Gary Bruce, President of PartnerTech North America, currently serves as ... significant amount of time in Sweden since joining PartnerTech based in Malmo, Sweden. ...
(Date:12/1/2015)... ... December 01, 2015 , ... Dr. Arash ... Modern Man for 2015. , Angeleno Magazine is a division of Modern ... in 1994, Modern Luxury includes more than 50 magazine titles across 15 major ...
Breaking Medicine News(10 mins):